Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 109 clinical trials
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if …

  • 432 views
  • 04 Oct, 2022
  • 114 locations
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy …

  • 5 views
  • 04 Oct, 2022
  • 85 locations
Virtual Reality for Children in Radiotherapy (REVER)

For a young patient, the conditions of proton therapy treatment can be stressful. Adjusting the environment can be a source of avoiding this physical and psychological discomfort impacting the

  • 0 views
  • 01 Nov, 2021
  • 1 location
Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial

The standard treatment of unresectable hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE) or sorafenib. Though the TACE and the agent showed survival benefit in several randomized phase III trials, the benefit was modest. Recently, radiotherapy (RT), especially conformal and higher dose with the advancement of RT techniques, showed favorable response …

neutrophil count
carcinoma
chemoembolization
unresectable hepatocellular carcinoma
hepatocellular carcinoma
  • 18 views
  • 22 Jan, 2021
  • 1 location
Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer (PARC)

This is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and

cancer chemotherapy
metastasis
neutrophil count
abraxane
platelet count
  • 0 views
  • 15 Sep, 2022
  • 2 locations
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy (PROTECT)

The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).

squamous cell carcinoma
skin cancer
esophagus cancer
neutrophil count
carcinoma
  • 0 views
  • 06 Jun, 2022
  • 1 location
Proton Therapy for Esophageal Cancer

The goal of this phase II study is to investigate the feasibility, toxicity and efficacy of a regimen incorporating a proven systemic regimen, carboplatin /paclitaxel, with conformal proton modality, followed by definitive surgery. In most combined-modality trials to date, chemotherapy regimens have included cisplatin, usually in conjunction with 5-fluorouracil. In …

x-rays
cancer
esophagus cancer
neutrophil count
serum pregnancy test
  • 77 views
  • 11 Mar, 2022
  • 1 location
Prostate Cancer - Localized Adenocarcinoma Proton Therapy

A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma

cancer
  • 11 views
  • 24 Feb, 2022
  • 1 location
Proton Therapy in the Treatment of Liver Metastases

substantial role in the treatment of metastatic liver cancer to treat unresectable disease. The dosimetric advantage of proton therapy may lead to improved clinical outcomes with less morbidity, however

stereotactic body radiotherapy
cancer
metastasis
stereotactic body radiation therapy
neutrophil count
  • 116 views
  • 10 Mar, 2022
  • 1 location
PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer (PROTECT)

This prospective, multicenter, nonrandomized phase-II-trial investigates in clinical practice the differences between intensity modulated proton therapy (IMPT) and standard intensity-modulated

squamous cell carcinoma
treatment regimen
metastasis
carcinoma
brachytherapy
  • 0 views
  • 16 Jun, 2022
  • 1 location